UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934
AUGUST 18, 2005
Date of Report (date of Earliest Event Reported)
ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
001-31564 |
|
87-0458888 |
|
(State or
Other Jurisdiction of |
|
(Commission File No.) |
|
(I.R.S. Employer Identification No.) |
405 EAGLEVIEW BLVD., EXTON, PA 19341
(Address of principal executive offices and zip code)
(484) 713-6000
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Item 8.01 Other Events.
Isolagen, Inc. (“Company”) announced that the Company and certain of its current and former officers and directors have been named as Defendants in securities litigation filed in the United States District Court for the Southern District of Texas. The action purports to be a class action brought on behalf of all persons who purchased publicly trade securities of Isolagen between March 3, 2004 and August 1, 2005. The Complaint asserts claims under section 10(b) and 20(a) of the Exchange Act. The Company and the individual Defendants have engaged counsel and expect to file a Motion to Dismiss the Complaint under the provisions of the Private Securities Litigation Reform Act of 1995.
[THE SIGNATURE PAGE FOLLOWS.]
2
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
ISOLAGEN, INC. |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: |
|
August 22, 2005 |
|
By: |
|
/s/ Martin Schmieg |
|
|
|
|
|
|
|
|
Martin Schmieg |
|
3